Patents by Inventor Keigo Saito

Keigo Saito has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10781249
    Abstract: An object of the present invention is to provide: an anti-GPC3 antibody that recognizes an epitope different from that for existing antibodies (e.g., GC33 and GC199) and can specifically bind, even in the form of single chain antibody, to GPC3 localized on a cell membrane; CAR comprising the anti-GPC3 single chain antibody; an immunocompetent cell expressing the CAR; a gene of the anti-GPC3 antibody or a gene of the CAR; a vector comprising the anti-GPC3 antibody gene or the CAR gene; a host cell in which the vector has been introduced; a method for specifically detecting GPC3; and a kit for specifically detecting GPC3. An antibody comprising particular heavy chain CDR1 to CDR3 and particular light chain CDR1 to CDR3 defined in claim 1, and specifically binding to a human-derived GPC3 polypeptide specifically binds to GPC3 localized on a cell membrane. CAR-immunocompetent cells prepared on the basis of CAR comprising such single chain antibody are useful for cancer immunotherapy.
    Type: Grant
    Filed: August 21, 2019
    Date of Patent: September 22, 2020
    Assignees: Yamaguchi University, National Cancer Center, Noile-Immune Biotech, Inc.
    Inventors: Koji Tamada, Yukimi Sakoda, Tetsuya Nakatsura, Keigo Saito
  • Patent number: 10730935
    Abstract: An object of the present invention is to provide: an anti-GPC3 antibody that recognizes an epitope different from that for existing antibodies (e.g., GC33 and GC199) and can specifically bind, even in the form of single chain antibody, to GPC3 localized on a cell membrane; CAR comprising the anti-GPC3 single chain antibody; an immunocompetent cell expressing the CAR; a gene of the anti-GPC3 antibody or a gene of the CAR; a vector comprising the anti-GPC3 antibody gene or the CAR gene; a host cell in which the vector has been introduced; a method for specifically detecting GPC3; and a kit for specifically detecting GPC3. An antibody comprising particular heavy chain CDR1 to CDR3 and particular light chain CDR1 to CDR3 defined in claim 1, and specifically binding to a human-derived GPC3 polypeptide specifically binds to GPC3 localized on a cell membrane. CAR-immunocompetent cells prepared on the basis of CAR comprising such single chain antibody are useful for cancer immunotherapy.
    Type: Grant
    Filed: August 21, 2019
    Date of Patent: August 4, 2020
    Assignees: Yamaguchi University, National Cancer Center, Noile-Immune Biotech, Inc.
    Inventors: Koji Tamada, Yukimi Sakoda, Tetsuya Nakatsura, Keigo Saito
  • Publication number: 20190367634
    Abstract: An object of the present invention is to provide: an anti-GPC3 antibody that recognizes an epitope different from that for existing antibodies (e.g., GC33 and GC199) and can specifically bind, even in the form of single chain antibody, to GPC3 localized on a cell membrane; CAR comprising the anti-GPC3 single chain antibody; an immunocompetent cell expressing the CAR; a gene of the anti-GPC3 antibody or a gene of the CAR; a vector comprising the anti-GPC3 antibody gene or the CAR gene; a host cell in which the vector has been introduced; a method for specifically detecting GPC3; and a kit for specifically detecting GPC3. An antibody comprising particular heavy chain CDR1 to CDR3 and particular light chain CDR1 to CDR3 defined in claim 1, and specifically binding to a human-derived GPC3 polypeptide specifically binds to GPC3 localized on a cell membrane. CAR-immunocompetent cells prepared on the basis of CAR comprising such single chain antibody are useful for cancer immunotherapy.
    Type: Application
    Filed: August 21, 2019
    Publication date: December 5, 2019
    Applicants: YAMAGUCHI UNIVERSITY, NATIONAL CANCER CENTER, NOILE-IMMUNE BIOTECH, INC.
    Inventors: KOJI TAMADA, YUKIMI SAKODA, TETSUYA NAKATSURA, KEIGO SAITO
  • Publication number: 20190359698
    Abstract: An object of the present invention is to provide: an anti-GPC3 antibody that recognizes an epitope different from that for existing antibodies (e.g., GC33 and GC199) and can specifically bind, even in the form of single chain antibody, to GPC3 localized on a cell membrane; CAR comprising the anti-GPC3 single chain antibody; an immunocompetent cell expressing the CAR; a gene of the anti-GPC3 antibody or a gene of the CAR; a vector comprising the anti-GPC3 antibody gene or the CAR gene; a host cell in which the vector has been introduced; a method for specifically detecting GPC3; and a kit for specifically detecting GPC3. An antibody comprising particular heavy chain CDR1 to CDR3 and particular light chain CDR1 to CDR3 defined in claim 1, and specifically binding to a human-derived GPC3 polypeptide specifically binds to GPC3 localized on a cell membrane. CAR-immunocompetent cells prepared on the basis of CAR comprising such single chain antibody are useful for cancer immunotherapy.
    Type: Application
    Filed: January 10, 2018
    Publication date: November 28, 2019
    Applicants: Yamaguchi University, National Cancer Center, Noile-Immune Biotech, Inc.
    Inventors: Koji TAMADA, Yukimi SAKODA, Tetsuya NAKATSURA, Keigo SAITO
  • Publication number: 20190066846
    Abstract: The present invention relates to a method for assisting recurrence risk prediction for hepatocellular carcinoma patients. The method comprises measuring glypican 3 (GPC3) peptide recognized by both a first monoclonal antibody and a second monoclonal antibody in a blood sample of a hepatocellular carcinoma patient, by contacting the sample with the first monoclonal antibody that recognizes a peptide having an amino acid sequence in the N-terminal side of GPC3 and the second monoclonal antibody that recognizes a peptide having an amino acid sequence in the C-terminal side of GPC3, and detecting the complex comprising GPC3 peptide, the first antibody and the second antibody.
    Type: Application
    Filed: September 7, 2018
    Publication date: February 28, 2019
    Applicants: SYSMEX CORPORATION, NATIONAL CANCER CENTER
    Inventors: Tetsuya NAKATSURA, Keigo SAITO, Masahiro MIURA, Kozo SUTO, Takuya IINO
  • Patent number: 9465030
    Abstract: Provided is a kit for diagnosing at a high reproducibility, said kit being produced by preparing a monoclonal antibody against GPC3 and a monoclonal antibody against SPARC that are superior in quality stability to commercially available and commonly employed antibodies, and using these antibodies.
    Type: Grant
    Filed: June 17, 2013
    Date of Patent: October 11, 2016
    Assignees: NATIONAL CANCER CENTER, LSIP, LLC
    Inventors: Tetsuya Nakatsura, Keigo Saito
  • Publication number: 20150198598
    Abstract: Provided is a kit for diagnosing at a high reproducibility, said kit being produced by preparing a monoclonal antibody against GPC3 and a monoclonal antibody against SPARC that are superior in quality stability to commercially available and commonly employed antibodies, and using these antibodies.
    Type: Application
    Filed: June 17, 2013
    Publication date: July 16, 2015
    Applicants: LSIP, LLC, NATIONAL CANCER CENTER
    Inventors: Tetsuya Nakatsura, Keigo Saito